Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 11 November 2019 – On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme, initiated 5 November 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 November 2019 to 3 February 2020.
Since the announcement of the programme, the following transactions have been made:
|6 November 2019||100,000||380.28||38,028,303|
|7 November 2019||100,000||379.78||37,978,466|
|8 November 2019||100,000||382.21||38,220,599|
|Accumulated under the programme||300,000||114,227,368|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 39,600 B shares in the period from 6 November 2019 to 8 November 2019. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 45,243,355 B shares of DKK 0.20, corresponding to 1.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 8 November 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 38,123,923 B shares at an average share price of DKK 341.20 per B share equal to a transaction value of DKK 13,007,899,986.
|Anne Margrethe Hauge||+45 4442 firstname.lastname@example.org|
|Ken Inchausti (US)||+1 609 240 email@example.com|
|Peter Hugreffe Ankersen||+45 3075 firstname.lastname@example.org|
|Valdemar Borum Svarrer||+45 3079 email@example.com|
|Ann Søndermølle Rendbæk||+45 3075 firstname.lastname@example.org|
|Mark Joseph Root||+45 3079 email@example.com|
|Kristoffer Due Berg (US)||+1 609 235 firstname.lastname@example.org|
Company announcement 67 / 2019
Upcoming Life Sciences Events
- August 2020
- ChinaBio® Partnering Forum 2020 Digital
- Biotechgate Digital Partnering Event
- September 2020
- Basel: Pharma-Biotech Product & Company Valuation